Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines Corp. (BPMC)
:BPMC
BPMC Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Blueprint Medicines News
BPMC FAQ
What was Blueprint Medicines Corp.’s price range in the past 12 months?
Currently, no data Available
What is Blueprint Medicines Corp.’s market cap?
Currently, no data Available
When is Blueprint Medicines Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Blueprint Medicines Corp.’s earnings last quarter?
Currently, no data Available
Is Blueprint Medicines Corp. overvalued?
According to Wall Street analysts Blueprint Medicines Corp.’s price is currently Undervalued.
Does Blueprint Medicines Corp. pay dividends?
Blueprint Medicines Corp. does not currently pay dividends.
What is Blueprint Medicines Corp.’s EPS estimate?
Blueprint Medicines Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Blueprint Medicines Corp. have?
Currently, no data Available
What happened to Blueprint Medicines Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Blueprint Medicines Corp.?
Currently, no hedge funds are holding shares in BPMC
Company Description
Blueprint Medicines Corp.
Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on developing targeted treatments for genomically defined cancers, rare diseases, and cancer immunotherapy. The company leverages its proprietary scientific platform to create small molecule medicines that selectively target genetic drivers of disease. Blueprint Medicines aims to improve patient outcomes through the development of transformative therapies that address the underlying causes of various diseases.